Recently, the mTOR inhibitor everolimus was approved for the treatment of slow-growing TSC tumors in the CNS [47], and its predecessor sirolimus was shown to modulate AML and LAM [48], [49]. The gene discussed is MTOR; the disease is tuberous sclerosis.